LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
LQDA - Liquidia Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$77.64
DETAILS
HIGH:
$130.00
LOW:
$33.00
MEDIAN:
$60.00
CONSENSUS:
$77.64
UPSIDE:
128.76%
Stock News
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.
Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Why
Liquidia Corporation (NASDAQ: LQDA - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with a volume of 955,427 shares. Analyst Upgrades and Downgrades A number of equities research analysts have commented on the company. Wedbush
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)
A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options
LIQUIDIA CORPORATION INVESTIGATION: LQDA Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Liquidia securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Liquidia investors who lost money.
Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)
LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia's forecast of more than $1 billion in 2027 net revenue.
Liquidia (NASDAQ:LQDA) Stock Price Down 6.1% After Analyst Downgrade
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares dropped 6.1% on Monday after Wells Fargo and Company downgraded the stock from an overweight rating to an equal weight rating. Wells Fargo and Company now has a $30.00 price target on the stock. Liquidia traded as low as $25.92 and last traded at $26.8880. 1,088,644 shares
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
United Therapeutics Won Its Patent War and Liquidia Collapsed
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
Price Targets
Liquidia price target lowered to $58 from $72 at Needham
$58.00
(was $26.81)
Needham
Liquidia price target raised to $33 from $30 at Wells Fargo
$33.00
(was $26.81)
Wells Fargo
BTIG Upgrades Liquidia Technologies (LQDA) to Buy
$70.00
(was $26.81)
Julian Harrison
·
BTIG
Liquidia Technologies (LQDA) PT Lowered to $58 at H.C. Wainwright
$58.00
(was $27.99)
Wedbush
Liquidia price target lowered to $58 from $130 at H.C. Wainwright
$58.00
(was $27.99)
H.C. Wainwright
Liquidia downgraded to Equal Weight from Overweight at Wells Fargo
$30.00
(was $27.99)
Wells Fargo
Raymond James Downgrades Liquidia Technologies (LQDA) to Outperform
$53.00
(was $30.26)
Ryan Deschner
·
Raymond James
Liquidia price target raised to $106 from $68 at Raymond James
$106.00
(was $78.45)
Raymond James
Liquidia price target raised to $108 from $62 at Wells Fargo
$108.00
(was $78.79)
Wells Fargo
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$129.00
(was $89.03)
Piper Sandler
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$130.00
(was $89.03)
RBC Capital
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$36.00
(was $89.03)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$130.00
(was $89.03)
Stephens
Liquidia price target raised to $130 from $75 at H.C. Wainwright
$130.00
(was $89.11)
H.C. Wainwright
Liquidia price target raised to $109 from $59 at BTIG
$109.00
(was $71.07)
BTIG
Liquidia price target raised to $75 from $67 at H.C. Wainwright
$75.00
(was $62.54)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$28.00
(was $62.54)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$75.00
(was $62.54)
Oppenheimer
Raymond James sees positive readthrough for Liquidia from Hikma v. Amarin
$68.00
(was $62.54)
Raymond James
Liquidia price target raised to $67 from $55 at H.C. Wainwright
$67.00
(was $53.50)
Andrew Fein
·
H.C. Wainwright